Back to Authors

Risacher, Shannon L.

https://orcid.org/0000-0002-3304-7943

Mayo Clinic

Indiana University Indianapolis

Citations 53

O4‐01‐01: Classification of MCI and Alzheimer's disease from CSF biomarkers: An ADNI study of Aß, tau and P‐tau versus 83 proteomic analytes
Yan, Jingwen , Shaw, Leslie M. , Trojanowski, John Q. , Aisen, Paul, Petersen, Ronald C. , Weiner, Michael W. , Li, Taiyong , Kim, Sungeun , Swaminathan, Shanker , Risacher, Shannon L. , Saykin, Andrew J. , Shen, Li

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2012.05.1634 Get It

P3‐212: Hippocampal subfield atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort: Relationships to diagnosis and memory impairment
Boddu, Mohan, West, John D. , Wan, Jing , Weiner, Michael W. , Initiative, The Alzheimer's Disease Neuroimaging, Ramanan, Vijay K. , Shen, Li , Risacher, Shannon L. , Kim, Sungeun , Wang, Yang , Crane, Paul K. , Jack, Clifford R. , Saykin, Andrew J. , Initiative, The Alzheimer's Disease Neuroimaging

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2012.05.1434 Get It

Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans
Saykin, Andrew J. , Shen, Li , Potkin, Steven G. , Swaminathan, Shanker , Kim, Sungeun , Risacher, Shannon L. , Huentelman, Matthew J. , Craig, David W. , Thompson, Paul M. , Stein, Jason L. , Moore, Jason H. , Farrer, Lindsay A. , Jack, Clifford R. , Weiner, Michael W. , Initiative, Alzheimer's Disease Neuroimaging, Foroud, Tatiana , Nho, Kwangsik T. , Green, Robert C. , Bertram, Lars , Initiative, Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Shen, Li , Stein, Jason L , Thompson, Paul M

Alzheimer's & Dementia | May 7, 2010 | Volume: 6 | Issue: 3 | Pages: 265-273

10.1016/j.jalz.2010.03.013 Get It

The role of the Alzheimer's Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome‐wide association studies (GWAS) of longitudinal phenotypic data, and (3) providing a central resource, point of contact and planning group for genetics within the Alzheimer's Disease Neuroimaging Initiative. Genome‐wide array data have been publicly released and updated, and several neuroimaging GWAS have recently been reported examining baseline magnetic resonance imaging measures as quantitative phenotypes. Other preliminary investigations include copy number variation in mild cognitive impairment and Alzheimer's disease and GWAS of baseline cerebrospinal fluid biomarkers and longitudinal changes on magnetic resonance imaging. Blood collection for RNA studies is a new direction. Genetic studies of longitudinal phenotypes hold promise for elucidating disease mechanisms and risk, development of therapeutic strategies, and refining selection criteria for clinical trials.